Like thousands of medicinal chemists across the world I frequently spin my magnetic bars overnight, scratch round bottom flasks next morning as if the molecules are hiding somewhere in the flask walls and look at my harvest anxiously standing around my dirty and disorganized chemical hood hoping that NMR and Mass will be okay and my hunt for that elusive molecule which is going to help someone rid of his/her disease to some extent is finally complete. In this tryst, I combine alphabets of cancer biology, tumor immunology, medicinal chemistry and some rudimentary pharmacology and drug design concepts and in vitro and in vivo models of tumors for screening; and seek guidance from molecular modeling/virtual screening experts and most recently with some extraterrestrial artificial intelligence (AI) nerds to design a drug-like molecule against a protein target which physicians or researchers believe has gone awry (based on their trust in p values) and is making some one sick.
In team with renowned physicians, immunologists, cancer biologists and molecular modelling colleagues sitting in different continents and those extraterrestrial AI nerds situated somewhere on the west coast I currently focus on developing small molecule based immunotherapeutics for treatment of high-risk malignancies such as but not limited to:
• Ovarian cancer
• Pancreatic cancer
• Colorectal cancer
Complexities of drug-discovery commerce aside, small molecule based immunotherapeutics can be a viable alternative or a great complementary armamentarium to antibody based immunotherapies for treatment of high-risk malignancies or diseases.
M.Phil | India-Birla Institute of Tech and Science
PhD | India-Jamia Millia Islamia-Delhi
1999 - 2001
Ranbaxy Research Fellowship
Sponsor: Ranbaxy Research Laboratories
1997 - 1998
Senior Research Fellowship
Sponsor: Council of Scientific and Industrial Research (CSIR)
James NE, Cantillo E, Oliver MT, Rowswell-Turner RB, Ribeiro JR, Kim KK, Chichester CO, DiSilvestro PA, Moore RG, Singh RK, Yano N, Zhao TC. "HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells." Clinical and experimental immunology.. 2018 Sep 0; 193(3):327-340.
Ribeiro JR, Schorl C, Yano N, Romano N, Kim KK, Singh RK, Moore RG. "HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells." Journal of ovarian research.. 2016 May 17; 9(1):28. Epub 2016 May 17.
Kim KK, Han A, Yano N, Ribeiro JR, Lokich E, Singh RK, Moore RG. "Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers." Scientific reports.. 2015 Nov 16; 5:15911. Epub 2015 Nov 16.
VIEW ALL PUBLICATIONS